Specifically with insulin the problem is evergreening. The big companies make small, incremental improvements to the brand-name drug which allows them to extend

Specifically with insulin the problem is evergreening. The big companies make small, incremental improvements to the brand-name drug which allows them to extend their patent. This makes sense when the improvements are significant, but there needs to be some lower-bound to how different the drugs can be before a patent is extended.